Promising survival in patients with high-grade gliomas following therapy with a novel boronated porphyrin

J Clin Neurosci. 2003 Jul;10(4):425-7. doi: 10.1016/s0967-5868(03)00062-6.

Abstract

Current treatment strategies for high-grade gliomas are inadequate with high rates of disease recurrence and poor overall survival. Photodynamic therapy has been extensively investigated for a variety of tumours including high-grade gliomas. We have previously described a novel boronated porphyrin (BOPP) which has highly selective uptake by tumour cells. A Phase I study documented that BOPP at a dose of 4mg/kg was well tolerated. We report here the survival data arising from this Phase I study. Overall 28 patients (pts) with high-grade gliomas were treated with BOPP photodynamic therapy with a median overall survival (OS) of 14 months (2-48+ months). Sixteen pts had glioblastoma multiforme (GBM) with a median OS of 8 months (2-38+). Of 9 pts with recurrent GBM, the median OS was 11 months (3-38+), with 56% surviving at least 12 months. In conclusion, BOPP photodynamic therapy was associated with encouraging survival particularly in the recurrent GBM setting.

Publication types

  • Clinical Trial, Phase I

MeSH terms

  • Adult
  • Aged
  • Boron Compounds / adverse effects
  • Boron Compounds / therapeutic use*
  • Boron Neutron Capture Therapy
  • Deuteroporphyrins / adverse effects
  • Deuteroporphyrins / therapeutic use*
  • Disease Progression
  • Dose-Response Relationship, Radiation
  • Female
  • Glioma / mortality*
  • Glioma / pathology
  • Glioma / radiotherapy*
  • Humans
  • Male
  • Middle Aged
  • Oligodendroglioma / mortality
  • Oligodendroglioma / radiotherapy*
  • Survival Rate
  • Survivors

Substances

  • 2,4-(alpha,beta-dihydroxyethyl)deuteroporphyrin IX tetrakiscarborane carboxylate ester
  • Boron Compounds
  • Deuteroporphyrins